ZeroStack Corp. continues to juggle its dual business lines, combining a global pharmaceutical distribution operation via its subsidiary Phatebo with a pioneering decentralized AI treasury centered on 0G Tokens and other digital assets. The May 2026 quarterly report spotlights ongoing strategic cryptocurrency acquisitions alongside steady pharma revenue generation, illustrating their hybrid growth approach. However, regulatory uncertainty following recent SEC interpretations around cryptocurrency securities classification poses a notable risk to operational flexibility and financial stability.